Brain

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling…

2 months ago

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling…

2 months ago

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling…

2 months ago

Synergy CHC Corp. (NASDAQ: SNYR) Announces FOCUSfactor® Named #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026

Pharmacy Times Annual Survey Recognizes FOCUSfactor as the Leading Pharmacist-Recommended Brand in the Memory-Support CategoryWESTBROOK, Maine, Oct. 27, 2025 (GLOBE…

2 months ago

Synergy CHC Corp. (NASDAQ: SNYR) Announces FOCUSfactor® Named #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026

Pharmacy Times Annual Survey Recognizes FOCUSfactor as the Leading Pharmacist-Recommended Brand in the Memory-Support CategoryWESTBROOK, Maine, Oct. 27, 2025 (GLOBE…

2 months ago

Synergy CHC Corp. (NASDAQ: SNYR) Announces FOCUSfactor® Named #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026

Pharmacy Times Annual Survey Recognizes FOCUSfactor as the Leading Pharmacist-Recommended Brand in the Memory-Support CategoryWESTBROOK, Maine, Oct. 27, 2025 (GLOBE…

2 months ago

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core TechnologiesJACKSON CENTER, Pa., Oct. 27, 2025…

2 months ago

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core TechnologiesJACKSON CENTER, Pa., Oct. 27, 2025…

2 months ago

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core TechnologiesJACKSON CENTER, Pa., Oct. 27, 2025…

2 months ago

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use…

2 months ago